Lilly adds to pain pipeline with Asahi Kasei licensing deal
pharmaphorum
JANUARY 29, 2021
US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable.
52 
Let's personalize your content